Besides alterations in serum FGF19 levels, human NAFLD is characterized by marked changes of BA metabolism which have been suggested to contribute to disease activity by various mechanisms [30,31,32]. The gene discussed is FGF19; the disease is metabolic dysfunction-associated steatotic liver disease.